SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '1mu2'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1DF7_A_MTXA501_2
(DIHYDROFOLATE
REDUCTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 TRP B 239
ARG B 193
THR B 237
 None
 1.01A 1df7A-1mu2B:
undetectable		 1df7A-1mu2B:
17.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1IKW_A_EFZA2000_1
(POL POLYPROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.12A 1ikwA-1mu2A:
29.7		 1ikwA-1mu2A:
60.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IVV_A_DAHA382_1
(AMINE OXIDASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 THR B 288
ASN A 493
ASP A 459
TYR A 440
VAL A 492
 None
 1.44A 1ivvA-1mu2B:
undetectable		 1ivvA-1mu2B:
20.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IVV_B_DAHB382_1
(AMINE OXIDASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 THR B 288
ASN A 493
ASP A 459
TYR A 440
VAL A 492
 None
 1.45A 1ivvB-1mu2B:
undetectable		 1ivvB-1mu2B:
20.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1KLM_A_SPPA999_1
(HIV-1 REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		6 / 11 LEU A 100
LYS A 102
PRO A 225
TRP A 229
LEU A 234
TYR A 318
 None
 1.25A 1klmA-1mu2A:
28.7		 1klmA-1mu2A:
61.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1KLM_A_SPPA999_1
(HIV-1 REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		7 / 11 LEU A 100
LYS A 102
PRO A 226
TRP A 229
LEU A 234
PRO A 236
TYR A 318
 None
 0.82A 1klmA-1mu2A:
28.7		 1klmA-1mu2A:
61.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MAG_A_DVAA6_0
(GRAMICIDIN A)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 ALA A 368
VAL A 370
TRP A 337
 None
 0.95A 1magA-1mu2A:
undetectable		 1magA-1mu2A:
4.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MAG_B_DVAB6_0
(GRAMICIDIN A)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 ALA A 368
VAL A 370
TRP A 337
 None
 0.95A 1magB-1mu2A:
undetectable		 1magB-1mu2A:
4.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MXG_A_ACRA443_1
(ALPHA AMYLASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 8 THR B 290
ASN B 255
ASP B 256
LYS B 249
 None
 1.20A 1mxgA-1mu2B:
undetectable		 1mxgA-1mu2B:
20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_1
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 4 ILE A 364
LEU A 367
VAL A 371
ALA A 378
 None
 0.73A 1mz9A-1mu2A:
undetectable		 1mz9A-1mu2A:
5.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_1
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 4 ILE B 364
LEU B 367
VAL B 371
ALA B 378
 None
 0.84A 1mz9A-1mu2B:
undetectable		 1mz9A-1mu2B:
7.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_2
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 ILE A 364
LEU A 367
VAL A 371
 None
 0.27A 1mz9B-1mu2A:
undetectable		 1mz9B-1mu2A:
5.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_2
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 ILE B 364
LEU B 367
VAL B 371
 None
 0.47A 1mz9B-1mu2B:
undetectable		 1mz9B-1mu2B:
7.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_3
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 ILE A 364
LEU A 367
VAL A 371
ALA A 378
 None
 0.72A 1mz9C-1mu2A:
undetectable		 1mz9C-1mu2A:
5.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MZ9_A_VDYA1002_3
(CARTILAGE OLIGOMERIC
MATRIX PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 ILE B 364
LEU B 367
VAL B 371
ALA B 378
 None
 0.83A 1mz9C-1mu2B:
undetectable		 1mz9C-1mu2B:
7.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SV5_A_65BA600_0
(REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 LEU A 100
PRO A 225
TRP A 229
LEU A 234
TYR A 318
 None
 0.94A 1sv5A-1mu2A:
28.7		 1sv5A-1mu2A:
60.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1SV5_A_65BA600_0
(REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 LEU A 100
PRO A 226
TRP A 229
LEU A 234
TYR A 318
 None
 1.37A 1sv5A-1mu2A:
28.7		 1sv5A-1mu2A:
60.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T03_P_TFOP822_1
(POL POLYPROTEIN
SYNTHETIC
OLIGONUCLEOTIDE
PRIMER)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 ASP A 110
TYR A 183
ASP A 185
ASP A 186
 None
 0.87A 1t03A-1mu2A:
30.7		 1t03A-1mu2A:
60.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T03_P_TFOP822_1
(POL POLYPROTEIN
SYNTHETIC
OLIGONUCLEOTIDE
PRIMER)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 ASP A 110
TYR A 183
ASP A 186
LYS A 220
 None
 0.97A 1t03A-1mu2A:
30.7		 1t03A-1mu2A:
60.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1T03_P_TFOP822_1
(POL POLYPROTEIN
SYNTHETIC
OLIGONUCLEOTIDE
PRIMER)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 ASP A 110
TYR A 183
MET A 184
ASP A 185
 None
 1.24A 1t03A-1mu2A:
30.7		 1t03A-1mu2A:
60.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2CEO_B_T44B1395_1
(THYROXINE-BINDING
GLOBULIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 ALA B 101
GLN B 343
LEU B 325
LEU B 348
ARG B 384
 None
None
None
SO4  B1309 ( 3.6A)
None
 1.13A 2ceoB-1mu2B:
0.0		 2ceoB-1mu2B:
20.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2KOT_B_ANWB99_0
(PROTEIN S100-A13)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 8 ALA B  50
THR B 128
PHE B 130
THR B  58
 None
 1.06A 2kotB-1mu2B:
undetectable		 2kotB-1mu2B:
16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Q72_A_IXXA802_1
(TRANSPORTER)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 ILE A 504
SER A 507
ILE A 530
PHE A 481
 None
 1.17A 2q72A-1mu2A:
0.0		 2q72A-1mu2A:
22.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2V0Z_O_C41O1327_2
(RENIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 8 THR B 128
PRO B 150
LEU B 149
THR A  88
 None
 1.11A 2v0zO-1mu2B:
undetectable		 2v0zO-1mu2B:
21.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XN5_A_FUNA1356_2
(THYROXINE-BINDING
GLOBULIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 LEU A 282
ARG A 281
ILE A 283
 None
SO4  A1312 (-3.6A)
None
 0.57A 2xn5B-1mu2A:
undetectable		 2xn5B-1mu2A:
5.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ABL_W_CHDW1060_0
(CYTOCHROME C OXIDASE
POLYPEPTIDE 7A1
CYTOCHROME C OXIDASE
SUBUNIT 1)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 8 ILE A 180
LEU A 168
PHE A 171
LEU A 109
 None
 0.91A 3ablN-1mu2A:
2.1
3ablW-1mu2A:
0.0		 3ablN-1mu2A:
18.01
3ablW-1mu2A:
7.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ELZ_A_CHDA152_0
(ILEAL BILE
ACID-BINDING PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 VAL A 370
LYS A 373
HIS A 342
 None
 0.96A 3elzA-1mu2A:
undetectable		 3elzA-1mu2A:
14.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HS4_A_AZMA703_1
(CARBONIC ANHYDRASE 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 HIS B 360
TRP A 397
TRP A 401
ASP A 402
 None
 1.46A 3hs4A-1mu2B:
0.0		 3hs4A-1mu2B:
19.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3KO0_F_TFPF202_1
(PROTEIN S100-A4)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 11 ASP A 186
LEU A 168
PHE A 171
ILE A 180
SER A 215
 None
 1.46A 3ko0E-1mu2A:
0.0
3ko0F-1mu2A:
undetectable
3ko0G-1mu2A:
0.0
3ko0H-1mu2A:
undetectable		 3ko0E-1mu2A:
11.80
3ko0F-1mu2A:
11.80
3ko0G-1mu2A:
11.80
3ko0H-1mu2A:
11.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3KP6_B_SALB3004_1
(TRANSCRIPTIONAL
REGULATOR TCAR)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 LYS A 527
ILE A 494
PHE A 481
GLU A 523
 None
 1.08A 3kp6A-1mu2A:
0.0
3kp6B-1mu2A:
0.0		 3kp6A-1mu2A:
15.64
3kp6B-1mu2A:
15.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LN1_A_CELA682_2
(PROSTAGLANDIN G/H
SYNTHASE 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 8 LEU B 310
SER B 311
LEU B 260
ILE B 244
 None
 0.82A 3ln1A-1mu2B:
undetectable		 3ln1A-1mu2B:
21.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LN1_B_CELB682_2
(PROSTAGLANDIN G/H
SYNTHASE 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 LEU B 310
SER B 311
LEU B 260
ILE B 244
 None
 0.83A 3ln1B-1mu2B:
undetectable		 3ln1B-1mu2B:
21.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 ASP A 442
ASN A 544
SER A 444
 None
 0.93A 3lslA-1mu2A:
0.0
3lslD-1mu2A:
0.0		 3lslA-1mu2A:
18.10
3lslD-1mu2A:
18.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 SER A 444
ASP A 442
ASN A 544
 None
 0.85A 3lslA-1mu2A:
0.0
3lslD-1mu2A:
0.0		 3lslA-1mu2A:
18.10
3lslD-1mu2A:
18.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3M8P_A_65BA562_0
(REVERSE
TRANSCRIPTASE/RIBONU
CLEASE H
P51 RT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 11 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.13A 3m8pA-1mu2A:
29.8
3m8pB-1mu2A:
13.6		 3m8pA-1mu2A:
61.21
3m8pB-1mu2A:
60.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MEC_A_65BA561_0
(P66 REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.07A 3mecA-1mu2A:
29.8		 3mecA-1mu2A:
61.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MEC_A_65BA561_0
(P66 REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
TRP A 229
LEU A 234
PRO A 236
TYR A 318
 None
 0.80A 3mecA-1mu2A:
29.8		 3mecA-1mu2A:
61.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PGL_A_RZXA257_1
(CARBOXY-TERMINAL
DOMAIN RNA
POLYMERASE II
POLYPEPTIDE A SMALL
PHOSPHATASE 1)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 PHE A 481
VAL A 532
ILE A 530
SER A 507
 None
 0.96A 3pglA-1mu2A:
undetectable		 3pglA-1mu2A:
16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SGL_A_SAMA692_0
(TRNA
5-METHYLAMINOMETHYL-
2-THIOURIDINE
BIOSYNTHESIS
BIFUNCTIONAL PROTEIN
MNMC)		 1mu2 HIV-2 RT
HIV-2 RT
(Human
immunodeficiency
virus
2;
Human
immunodeficiency
virus
2) 		5 / 12 GLY A 542
GLY B 285
LEU B 282
VAL A 547
GLY A 540
 None
None
None
None
SO4  A1303 (-4.3A)
 1.01A 3sglA-1mu2A:
undetectable		 3sglA-1mu2A:
21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TGV_B_BEZB1_0
(HEME-BINDING PROTEIN
HUTZ)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 GLN B 372
PHE B 388
PRO B 411
LEU B 390
 None
 1.11A 3tgvB-1mu2B:
0.0		 3tgvB-1mu2B:
16.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TGV_D_BEZD1_0
(HEME-BINDING PROTEIN
HUTZ)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 GLN B 372
PHE B 388
PRO B 411
LEU B 390
 None
 0.99A 3tgvD-1mu2B:
0.0		 3tgvD-1mu2B:
16.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UVV_B_9CRB501_1
(RETINOIC ACID
RECEPTOR RXR-ALPHA)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 ALA A 268
ALA A 267
GLN A 269
ILE A 257
LEU A 246
 None
 0.95A 3uvvB-1mu2A:
undetectable		 3uvvB-1mu2A:
19.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VQR_A_ACTA1002_0
(PUTATIVE
OXIDOREDUCTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 GLY B 112
VAL B 111
ASP B 110
THR B 408
 None
 1.04A 3vqrA-1mu2B:
undetectable		 3vqrA-1mu2B:
19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VQR_B_ACTB1002_0
(PUTATIVE
OXIDOREDUCTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 GLY B 112
VAL B 111
ASP B 110
THR B 408
 None
 1.04A 3vqrB-1mu2B:
undetectable		 3vqrB-1mu2B:
19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BCS_A_ACTA1126_0
(CHIMERIC AVIDIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 4 THR B 338
GLN B 330
ARG B 423
THR B 418
 None
 1.48A 4bcsA-1mu2B:
0.0		 4bcsA-1mu2B:
17.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DV1_A_SRYA1601_1
(16S RRNA
RIBOSOMAL PROTEIN
S12)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 LYS A  16
LYS A  13
PRO A  14
 None
 1.24A 4dv1L-1mu2A:
0.0		 4dv1L-1mu2A:
15.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DV1_A_SRYA1601_1
(16S RRNA
RIBOSOMAL PROTEIN
S12)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 LYS B  16
LYS B  13
PRO B  14
 None
 0.89A 4dv1L-1mu2B:
0.0		 4dv1L-1mu2B:
15.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4HFP_B_15UB402_1
(PROTHROMBIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 HIS A 549
ALA A 537
GLY A 542
CYH B 280
GLY B 285
 SO4  A1303 (-4.2A)
None
None
None
None
 1.02A 4hfpB-1mu2A:
undetectable		 4hfpB-1mu2A:
19.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I41_A_MIXA500_2
(SERINE/THREONINE-PRO
TEIN KINASE PIM-1)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 4 LEU A 168
LEU A 212
GLN A 161
GLU B  49
 None
None
None
SO4  A1302 ( 4.9A)
 1.06A 4i41A-1mu2A:
undetectable		 4i41A-1mu2A:
19.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4K7A_A_MXDA1002_1
(ANDROGEN RECEPTOR)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		3 / 3 GLU A 233
TRP A 235
LYS A 243
 None
 1.23A 4k7aA-1mu2A:
0.0		 4k7aA-1mu2A:
17.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KM0_A_CP6A201_1
(DIHYDROFOLATE
REDUCTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 ILE A   8
THR A  84
LEU A  80
ILE A  10
THR A 163
 None
 1.32A 4km0A-1mu2A:
undetectable		 4km0A-1mu2A:
16.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4L1A_A_AB1A101_2
(MDR769 HIV-1
PROTEASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 ASP A 402
GLY B 363
PRO B 391
THR B 418
 None
 0.98A 4l1aB-1mu2A:
0.0		 4l1aB-1mu2A:
11.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WG0_L_CHDL103_0
(NUCLEAR RECEPTOR
COACTIVATOR 2)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 7 LEU B 279
LEU B 260
GLU B 305
LEU B 303
 None
 0.73A 4wg0L-1mu2B:
undetectable
4wg0M-1mu2B:
undetectable		 4wg0L-1mu2B:
5.45
4wg0M-1mu2B:
5.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4WNU_A_QDNA602_1
(CYTOCHROME P450 2D6)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 11 LEU A 234
LEU A 109
LEU A 100
ALA A 190
PHE A 221
 None
 1.14A 4wnuA-1mu2A:
undetectable		 4wnuA-1mu2A:
21.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4YPA_B_SAMB2304_0
(HISTONE-LYSINE
N-METHYLTRANSFERASE
ASH1L)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 GLY B 155
ASP B 185
ASN B  81
GLN B 151
ILE B  75
 None
None
GOL  B1401 (-4.0A)
None
None
 1.48A 4ypaB-1mu2B:
undetectable		 4ypaB-1mu2B:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CYM_A_T27A601_1
(HIV-1 REVERSE
TRANSCRIPTASE, P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.10A 5cymA-1mu2A:
28.6		 5cymA-1mu2A:
60.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CYM_A_T27A601_1
(HIV-1 REVERSE
TRANSCRIPTASE, P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 PRO A  95
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 0.97A 5cymA-1mu2A:
28.6		 5cymA-1mu2A:
60.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CYQ_A_T27A601_1
(HIV-1 REVERSE
TRANSCRIPTASE, P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.08A 5cyqA-1mu2A:
28.4		 5cyqA-1mu2A:
60.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5CYQ_A_T27A601_1
(HIV-1 REVERSE
TRANSCRIPTASE, P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 PRO A  95
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 0.93A 5cyqA-1mu2A:
28.4		 5cyqA-1mu2A:
60.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5EU8_B_010B6_0
(N-[(5-METHYLISOXAZOL
-3-YL)CARBONYL]ALANY
L-L-VALYL-N~1~-((1R,
2Z)-4-(BENZYLOXY)-4-
OXO-1-{[(3R)-2-OXOPY
RROLIDIN-3-YL]METHYL
}BUT-2-ENYL)-L-LEUCI
NAMIDE
MAIN PROTEASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 5 ASN B 306
LEU B 279
HIS B 278
CYH B 280
 None
 1.20A 5eu8A-1mu2B:
0.0		 5eu8A-1mu2B:
21.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5I8F_A_ML1A211_1
(PHENOLIC OXIDATIVE
COUPLING PROTEIN)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		4 / 6 VAL B 370
LYS B 373
VAL B 329
TYR B 339
 None
 0.83A 5i8fA-1mu2B:
2.0		 5i8fA-1mu2B:
18.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VLM_D_CVID301_1
(REGULATORY PROTEIN
TETR)		 1mu2 HIV-2 RT
HIV-2 RT
(Human
immunodeficiency
virus
2;
Human
immunodeficiency
virus
2) 		4 / 8 GLY A 383
GLU B  29
ILE A 385
GLN A 372
 None
 0.91A 5vlmD-1mu2A:
0.2		 5vlmD-1mu2A:
15.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YK2_A_ERYA501_0
(PROBABLE CONSERVED
ATP-BINDING PROTEIN
ABC TRANSPORTER)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 11 GLU A 451
GLY A 455
ASP A 442
ALA A 454
VAL A 547
 None
 1.15A 5yk2A-1mu2A:
2.3		 5yk2A-1mu2A:
22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A5Z_L_9CRL501_0
(RETINOIC ACID
RECEPTOR RXR-ALPHA)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 ALA A 268
ALA A 267
GLN A 269
ILE A 257
LEU A 246
 None
 0.92A 6a5zL-1mu2A:
undetectable		 6a5zL-1mu2A:
10.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6A60_D_9CRD501_0
(RETINOIC ACID
RECEPTOR RXR-ALPHA)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 ALA A 268
ALA A 267
GLN A 269
ILE A 257
LEU A 246
 None
 1.01A 6a60D-1mu2A:
undetectable		 6a60D-1mu2A:
10.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6BSG_A_EFZA601_1
(REVERSE
TRANSCRIPTASE P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.04A 6bsgA-1mu2A:
29.6		 6bsgA-1mu2A:
63.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6BSJ_A_EFZA601_1
(REVERSE
TRANSCRIPTASE P66
SUBUNIT)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 10 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.11A 6bsjA-1mu2A:
29.5		 6bsjA-1mu2A:
63.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6ELI_A_T27A701_1
(REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.10A 6eliA-1mu2A:
29.1		 6eliA-1mu2A:
61.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6ELI_A_T27A701_1
(REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 LEU A 100
PRO A 225
TRP A 229
LEU A 234
TYR A 318
 None
 0.98A 6eliA-1mu2A:
29.1		 6eliA-1mu2A:
61.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6ELI_A_T27A701_1
(REVERSE
TRANSCRIPTASE)		 1mu2 HIV-2 RT
(Human
immunodeficiency
virus
2) 		5 / 12 PRO A  95
LYS A 103
TRP A 229
LEU A 234
TYR A 318
 None
 1.01A 6eliA-1mu2A:
29.1		 6eliA-1mu2A:
61.25